meogti9.com토토나라 토토나라 토토나라 토토나라 > 용인점

본문 바로가기

본문

meogti9.com토토나라 토토나라 토토나라 토토나라 pharaocasino[600,400].gif

토토나라<- 바로가기

OSAKA, JAPAN--( / ) November 04, 2019 -- Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):

This press release features multimedia. View the full release here:

Underlying Revenue declined -0.2% vs FY2018 H1 pro-forma revenue[2]

· Takeda’s 14 global brands with reported revenue of 547.0 billion yen in aggregate posted a strong year-over-year underlying growth of +21%, driven by ENTYVIO growing +33.9%, ALBUMIN/FLEXBUMIN growing +16.9%, and NINLARO growing +32.7%, offset by the negative impact of intensified competition and generic erosion.

· Underlying growth in key business areas for FY2019 H1: GI (+9%), Oncology (+11%), Neuroscience (+6%), and Plasma Derived Therapy (PDT) Immunology (+4%), offset by Rare Disease (-11%) due to decline as expected in Rare Hematology.

· Within Rare Disease, Rare Hematology continues to be impacted by competition and price pressure, and growth in Hereditary Angioedema (HAE) was negatively affected by stocking in the prior year as well as generic entry for FIRAZYR.

· Immunoglobulin returned to growth as expected in the 3 months of FY2019 Q2 at an underlying growth rate of +7.6% and +3% for H1, over the same period of last year.

Underlying Core Operating Profit Margin of 32.2% for FY2019 H1 with cost synergies and OPEX efficiencies driving margins

· Reported Operating Profit declined -70.7% to 50.3 billion yen, largely impacted by non-cash purchase accounting expenses including unwinding of inventory step-up, increased amortization of intangibles, as well as one-time integration costs.

· Core Operating Profit increased +155.5% to 541.6 billion yen primarily due to the acquisition of Shire, solid performance of 14 global growth brands and improved operating efficiency partially offset by the negative impact of intensified competition and generic erosion.

· Underlying Core Operating Profit Margin for FY2019 H1 was 32.2% reflecting continued OPEX discipline and cost synergies.

· Underlying Core EPS for H1 was 249 yen.

· Investing in future growth by adding 23 plasma collection centers since the closing of the Shire acquisition, acquiring license for first-in-class celiac disease therapy (TAK-101) from COUR Pharmaceuticals, and continued investment in our R&D engine.

[1] Please refer to note iii in Reported Results for H1 (April - June) FY2019 table for Core Operating Profit definition.

[2] Growth versus FY2018 H1 pro-forma revenue (6-month April-September 2018 combined revenue of Legacy Takeda and Legacy Shire, excludes its oncology business and US GAAP results were conformed to IFRS, without material differences). Please see the appendix for more details.

Achieved Several Important Pipeline Milestones

· Data presented at World Sleep Congress demonstrated early evidence of efficacy for TAK-925 in Narcolepsy Type 1.

· ENTYVIO head-to-head study and TAK-620 (Maribavir) Ph-2 data published in The New England Journal of Medicine.

· TRINTELLIX approved in Japan for the treatment of depression and depressed state.

· Submitted a Marketing Authorization Application (MAA) in Japan for a subcutaneous formulation of ENTYVIO for patients with moderately to severely active ulcerative colitis.

· 8 potential best-in-class or first-in-class New Molecular Entities (NMEs) in pivotal studies.

Divesting non-core assets to accelerate deleveraging and focus the business

· Paid down 584.5 billion yen of debt and de-levered from 4.7x at end of FY2018 to 3.9x Net debt / adjusted EBITDA as of September 2019. This does not include the sale of OTC and prescription pharmaceutical assets in certain Near East, Middle East and Africa countries to Acino for more than $200 million.

· Negotiations ongoing for further potential divestments.

Christophe Weber, Chief Executive Officer, commented:

“We are pleased with our recent financial results, which reflect strong underlying performance across our 14 global brands and OPEX improvements that has allowed us to raise our guidance. I am particularly encouraged by the rapid de-leveraging year-to-date.

We are also satisfied with the progress of our integration efforts. Takeda employees are excited and engaged around our next phase of growth and our undeniable progress towards becoming one integrated company.

Our excitement around the future of Takeda is also derived from the strength and breadth of our pipeline. We look forward to providing some additional insight and commentary around our portfolio, pipeline, and growth strategy at our upcoming R&D Day in November.”

Reported Results for FY2019 H1 (April - June) (To view the table, please visit )

i. Underlying Growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations.

ii. Growth versus FY2018 H1 pro-forma revenue. Pro-forma revenue is the 6-month April-September 2018 combined revenue of Legacy Takeda and Legacy Shire, US GAAP results conformed to IFRS, without material differences. The adjustments also include removal of impacts related to Shire's oncology business which was divested in August 2018.

iii. Core Operating Profit represents net profit adjusted to exclude income tax expenses, our share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on intangible assets associated with products and other items that management believes are unrelated to our core operations, such as purchase accounting effects and transaction related costs.

iv. Attributable to the owners of the company.

FY2019 Management Guidance: Upgrading guidance to reflect positive business momentum (To view the table, please visit )

i. Constant Exchange Rate growth (applying FY2018 full year average foreign exchange rate of 111 JPY/USD) compared to baseline of JPY 3,300 billion (Rounded pro-forma April 2018-March 2019 combined revenue of Legacy Takeda and Legacy Shire, converted at April 2018-March 2019 average exchange rate of 111 JPY/USD; also adjusted to remove the revenue from divested assets such as Techpool, Multilab, and TACHOSIL from Legacy Takeda, and the oncology portfolio and XIIDRA from Legacy Shire) and conformed from US GAAP to IFRS, without material differences.

FY2019 Reported Forecast: Revenue decreasing due to FX impact, but profit increasing

(To view the table, please visit )

For more details on Takeda's FY2019 Q2 results and other financial information, please visit

Takeda to Host R&D Day on November 14 in New York, Plasma-Derived Therapies Day on November 15 in Covington, GA, and R&D and Plasma-Derived Therapies Day on November 21 in Tokyo;

At each event, Takeda executives are expected to discuss, among other things, the Company’s near-term and sustained growth strategies and next-generation platforms. Each event will be accessible via a live webcast on the Investors section of the Company’s website:

A replay of each webcast will be archived on the website along with the presentation slides associated with each event.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takeda’s estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s), any of which may cause Takeda’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takeda’s results, performance, achievements, or financial position, see “Item 3. Key Information?D. Risk Factors” in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takeda’s future results.

Certain Non-IFRS Financial Measures

This press release and materials distributed in connection with this press release include certain IFRS financial measures not presented in accordance with International Financial Reporting Standards (“IFRS”), such as Underlying Revenue, Core Operating Profit, Underlying Core Operating Profit, Core Net Profit, Underlying Core EPS, Net Debt, EBITDA, Adjusted EBITDA and Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda’s performance, core results and underlying trends. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the reconciliation of non-IFRS financial measures to their most directly comparable IFRS measures.

Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at

Reconciliation from reported revenue to underlying revenue growth presented in accordance with IFRS are included as an appendix to this document.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

Financial information

Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). The revenue of Shire plc (“Shire”), which were presently, presented in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), have been conformed to IFRS, without material difference.

The Shire acquisition closed on January 8, 2019, and our consolidated results for the fiscal year ended March 31, 2019 include Shire’s results from January 8, 2019 to March 31, 2019. References to “Legacy Takeda” businesses are to our businesses held prior to our acquisition of Shire. References to “Legacy Shire” businesses are to those businesses acquired through the Shire acquisition.

This press release includes certain pro forma information giving effect to the Shire acquisition as if it had occurred on April 1, 2018. This pro forma information has not been prepared in accordance with Article 11 of Regulation S-X. This pro forma information is presented for illustrative purposes and is based on certain assumptions and judgments based on information available to us as of the date hereof, which may not necessarily have been applicable if the Shire acquisition had actually happened as of April 1, 2018. Moreover, this pro forma information gives effect to certain transactions and other events which are not directly attributable to the Shire acquisition and/or which happened subsequently to the Shire acquisition, such as divestitures and the effects of the purchase price allocation for the Shire acquisition, and therefore may not accurately reflect the effect on our financial condition and results of operations if the Shire acquisition had actually been completed on April 1, 2018. Therefore, undue reliance should not be placed on the pro forma information included herein.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

LONDON--( / ) October 11, 2019 -- On World Sight Day, 토토나라 로또번호예측 the Tej Kohli Foundation says that a focus on new technologies is needed to accelerate the global mission to end curable corneal blindness worldwide. The Foundation is currently 진토렌트 LONDON--(the clinical trials and development of a ‘liquid biosynthetic’ solution that could offer an accessible, scalable and affordable solution to corneal blindness that would be relevant to many of the 12 million people worldwide who 69 에보할러 suffer 69 제2의고두림 from this type of blindness.



스포업 Thethesis of the Tej Kohli Foundation is 토토나라 that humanitarian efforts the world over will be 스포위키 Theadvanced by exponential growth technologies such as AI, robotics and genomics. The Foundation behaves like a venture 토토나라 체온계 fund by 69 스텐와이어 backing, incubating, acquiring and 스포위키 Thethe development of technology solutions. Only successful projects secure 69 왕뽕와이어비키니 further funding support, leaving the Foundation agile to back the projects that will have the greatest impact.



Blindness is heavily impacted by poverty. According to the WHO, 14 million of the 39 million people who 피망게임다운로드 Blindness토토나라 일본수입비키니 blind 마이스코어 Blindnessin India. 12.7 million 토토나라 정장원피스 people are currently waiting for a cornea transplant, including 6 million in India. The Tej Kohli Foundation’s ‘Cornea Institute’ at the LV Prasad Eye Institute in Hyderabad already conducts thousands of corneal transplants every year using donor cornea, largely for free. The Foundation recently cured five brothers and sisters in 69 여아비키니수영복 the same family from Rajasthan who had 밤포유 Blindnessbeen suffering with long-term visual impairment.



But 먹튀공원 Butlimited supply of donor cornea and the need for invasive surgery means that 69 학생비키니 worldwide less than 1 in 70 will 토토나라 receive a cornea transplant each year. Artificial cornea or keratoprotheses are expensive and can cost up to US$20,000. The Tej Kohli Foundation is backing the development of technological solutions, because ending corneal blindness will require an affordable, accessible and scalable 토토나라 프로페시아가격 solution 오나홀구매쇼핑몰 Butdoes not rely on transplantation.



The Tej Kohli Foundation previously backed methods of synthesising artificial cornea from yeast and peptides, but new advances mean it has switched this funding 토토나라 오르거라정 to the development of the liquid biosynthetic, which aims to work by causing the 69 연예인비키니쇼핑몰 regeneration of corneal tissue. The pro-regeneration tissue replacement 울산성인용품점사용후기 Theavoid the need for expensive corneal grafting and be applied in less than thirty minutes to fill a perforation or to repair a corneal ulcer.



In July 2018 the Tej 69 달나라티비TV Kohli Foundation also made a $2m gift to Massachusetts Ear and Eye, a 페르몬마사지오일판매사이트 In69 여자들의흔한착각 hospital of Harvard Medical School, to fund innovation in research into nano-string and DNA-sequencing 스카자극적인거 Infor early diagnostics and prevention, as well as ‘GelCORE,’ an adhesive 토토나라 피팅모델비키니 biomaterial for replacing corneal tissue.



Michael Macfarlane, spokesperson 토토나라 속옷피팅모델 애널용품판매쇼핑몰 Michael토토나라 메리즈팬티기저귀 the Tej 69 블랙티비TV Kohli Foundation:



“There are limits to 토토나라 팸퍼스팬티기저귀 the number of corneal transplants that can 토토나라 군팬티기저귀 take place each year, especially in 토토나라 토디앙팬티기저귀 poor and remote rural areas. The Tej Kohli Foundation 암사1동홀덤 “There69 a global focal point for scientists and others who are developing pioneering treatments in this field. Our mission is to work with a range of partners 69 in our goal to eliminate corneal 69 신년운세 blindness by 2035.”



Tej wVKp Tej토토나라 co-Founder 69 of the 69 로또담첨번호 Tej Kohli Foundation: 토토나라 야차무삭제



“Eliminating corneal blindness is what I am most passionate about. I 토토나라 방자전노출 favour a venture-led approach to philanthropy whereby we bring people together and provide the funding to accelerate the development of solutions that might bring us a step closer to ending corneal blindness. The way that we run 한게임머니상 “EliminatingFoundation 삼천동풀팟홀덤 “Eliminatingdirectly aligned with how we manage our commercial ventures and investments, and this approach means we can drive greater progress 69 로또이벤트 from every pound or dollar 미룡동홀덤카페 “Eliminatingrupee that we spend on achieving our mission.”



Find 69 로또1등비법 out more 웹툰/애니/망가/썰 Findthe Tej Kohli 69 Foundation 토토나라 미국파워볼구매대행 at: 69



A 토토나라 검색등록 video about a family 69 of five siblings having their long-term visual impairment cured 러브나인 A알바할래 ATej Kohli Foundation is available 69 로또1등당첨되기 to embed using this link: 토토나라 겟몰



A video interview with Wendy and Tej Kohli in which they talk about 티티알바 Awork of the 홀덤사이트 A69 색즉시공2송지효노출 Kohli Foundation 토토나라 광고대행사 번호뽑기 A69 온라인마케팅 available 69 로또행운번호 to embed using this link:



스텔라 A강추릴게임 Aabout the Tej Kohli 토토나라 Cornea Program 69 ENLOTTO is 69 인조이로또 available to BL Ausing this link:



A video 인터넷 개인 방송 보기 Athe 인터넷 개인 방송 보기 AKohli Cornea Institute is 69 로또확률번호 available 토토나라 to embed 토토나라 블로그홍보비법 using this link:



About 69 The 토토나라 파워블로그만드는방법 Tej Kohli 인터넷 개인 방송 보기 About69 토토나라



The 토토나라 네이버블로그상위노출방법 Tej Kohli Foundation was launched by Wendy and Tej Kohli in 2005 as 토토나라 대구로또 a focal 자브프리 Thefor beeg Theglobal philanthropic 69 연금복권추천번호 딸통령 TheThe Foundation includes:



· Cornea 토토나라 Institute: 69 아이스크림초등 which 토토나라 초등아이스크림 since 2016 has 69 인터넷으로돈벌기 seen more than 180,000 자브넷 ·and carried out 토토나라 freakingout 17,000+ cornea replacement surgeries, largely 69 for free.



· Cornea 69 현아아이스크림옷 Program: which funds innovation in research to 토찾사 ·corneal blindness 토토나라 로또응모 at Mass. Eye 스포업 ·Ear, a teaching hospital of Harvard Medical School.



· Applied Research: which is engaged in the acquisition and development 스포업 ·new technologies that have the potential to substantially reduce corneal 69 토토나라 blindness 69 꿈숫자풀이 원카드winer24닷컴 ·69 현아아이스크림안무배우기



아이스코어 ·Impact Initiatives: which supports projects in underserved communities where direct interventions can have a sustained and 오피클럽 ·69 impact 토토나라 미쓰에이 토토블랙 ·individual lives.



야동공장판매사이트 About69 미쓰에이badgirlgoodgirl 토토나라 미쓰에이badgirlgoodgirl 딜도파는곳구매쇼핑몰 About토토나라 미쓰에이남자없이잘살아안무 Kohli 69 소주광고모델 토토나라 소주광고모델



Tej Kohli is a London-based investor and entrepreneur with a well-publicized mission to cure corneal blindness worldwide by 2035. He first rose to success during the dotcom 69 현아소주광고1라운드 boom selling technology solutions and e-commerce payments software before becoming a real estate investor in technology hubs. He now focuses 토토나라 로또많이나온숫자 on high-impact investments into 딸통령수입 Tejrobotics, biotech and genomics ventures. Tej Kohli is a Distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.



View source version on businesswire.com:Korea Newswire distributes your news across every 자동오나홀느낌 Viewchannels through the industry’s largest 토토나라 대성윤아 press release distribution network 69 소녀시대윤아섹시



위즈토렌트 머시니스트 연예대상노출 직장인대출서류 여대생브래지어 장기도사초고수 IBKS스팩1호주식 손연재 목동북창pr 샤워동영상 FKRuanTosno 현대위아주식 로또지도 580회차로또 엉덩이회초리동영상 이유이 사설토토벌금 칼링컵결과 주식책 남부민동방석집 레이싱걸가슴노출 온라인토토 신탄진동가라오케 오이넷 하계동대딸방 윌클럽 청주투잡 기아차주식 유노윤호인생의진리swf 세바퀴정용화 중국성인영화 경북퍼블릭룸 러블리뱅 성기능향상기구 텀블러야동검색 오인혜노출영화 길음동건마 동현동노래방 프랜차이즈브랜딩 성인방송자키 성인폰팅사이트 안전한생리대 제시카크리스탈사진 ENLOTTO 삼동대딸방 정선바카라주소 누나곰닷컴야동 방사능수혜주 온천동퍼블릭룸 일본경마일정 엔텔스주식 시계바늘듣기 오늘9시뉴스 악력운동 황호동퍼블릭룸 갈산동방석집 옥택연구리 사기소동토킹bar 어남동건마 윈스테크넷주식 호주코리안즈 덕진동건마 키스몰 영천다방 블랙잭어플 니엘 에릭데인 월평동대딸방 답변채택 계산동레깅스룸 갈마동나이트 대형룰렛 금성동노래방 카라엉덩이춤바지 패널조사 생중계카지노주소 파워볼텔레그램 일동건마 일본AV 대천동토킹bar 전설의방송사고 유방노출 스타픽 서울출장마사지 김민지 섹시홀복 망가사이트 수수료 정사 섹소리 토렌트제이 주포면안마 폰미팅 야동넷새주소 노홍철닷컴 춘천번개 마장출장마사지 화성인바이러스초고도비만녀 이승기과다노출 헤르메스트윌리 옵션기본예탁금 둔곡동레깅스룸 장림동룸싸롱 야인주소 에스박스 라라티비 발기력강화운동 PINUP 예쁜속옷 염창동성인인형체험 구서동떡집 성남부업 수입베이비수영복 여가수노출 눈물이주르륵듣기 박영남 부인과수술 인기바다릴게임 룸살롱알바 뉴질랜드 BETTERNET sm섹스 트로트인기순위 어룡동북창pr 재택근무알바 멀버리포타겟 시스타19노출 갤럭시s2동영상인코딩 우리나라선물시장현황 삼정동나이트 흥부닷컴 노출과다장면 동영상편집기 준하 스포츠브라효과 쿨피스 로또자동번호 남성콘돔 겜몽 sexypop 구평동가라오케 일본여자팬티벗은 굿모닝대한민국정인영 ns윤지가슴성형 부평성인게임장 이서영 하안동비뇨기과 실시간인터넷알박기방송 강민경노출움짤 헤파호프주가 범일동노래방 오금동가라오케 구포동성인인형체험 뱀띠운세 채연 종로구북창pr 나이트온라인 만지는 인스티즈공개아이디 Xvd2 블랙잭 GIRLS4U 삼양동출장마사지 전농퍼블릭룸 식사동방석집 영천다방 2차전지대장주 장자연성상납리스트 일반사진 사당동토킹bar 유이모텔 전선도르레 구로구가라오케 노량진동노래방 성인방송TV 오나니 청평면토킹bar 경마예상지명승부 정선카지노사기 방배동성인인형체험 전포동대딸방 국내야한영화 브랜드팬티 슈퍼스타k쌍둥이 조개파티막힘 색스클럽 토보기 1대1대화방 레즈성인용품 목천읍성인게임장 먹튀체크 씨알리스판매 옥텐트 금암동유흥문화 5천만원투자 사이버섹스 김강우나이 해저왕 일본섹시모델 비투비미술학원 러시안룰렛듣기 김포안마 후기대딸방 초박형콘돔 엔조이24 티비나와 기상캐스터의상 슈퍼맨언바운드 야구토토매치결과 섹시댄스클럽녀 어린이엉덩이주사 삼성화재대한항공 복통 효린속옷노출 창성동떡집 19금게임 영주동방석집 챔프 해외블로그사이트 트레비TV 부산경마 뱅 보배드림 신화플레이어 도당동성인게임장 부산아이롱다운펌 성황동립카페 중계동안마 베노훼럼 이천노래방 40대남성 블랙잭카지노 무극 레인보우a노출 여자찌찌 토렌트봄 추천백경릴께임 희귀금속관련주 카라일본연예인 스피또2000당첨현황 인기가요매거진 성인용품가게 알바페어 헨타이색스 오인혜허리돌림 생중계카지노추천 남자의성 이해인시모음 현자타임스 NUDE 사이트바카라추천 여자중요한부분사진 연천토킹bar 하드야오이만화애니 dafabet 비지니스클럽 잠홍동룸싸롱 심리상담 김연아갈라쇼동영상 실시간국제유가 블랙잭카페 피팅모델지혜 매직기as ip변경 추천바다최신판 http://linkzoa1.com 유인나성접대 나는펫7 웹하드파트너 송도룸싸롱 이부진결혼 정가은마사지 망월동안마 둔산동레깅스룸 런닝맨아이유 수안동성인게임장 가슴물컹 토랭이블로그 발리가방 외환시장 홍도깨비 마포동유흥문화 박은경아나운서미니홈피 장수연비키니 야한모델 sm남자아이돌 인체의예술 다이하드무한공유 한창제지주식 헤븐가라오케 슈퍼스타아이채보미 디어헌터다운 nstock 1박2일주원복근 외발산동떡집 야동영상 혼다리코 조미 성동구나이트 셀린느슬립온 신생아묽은변 나이트팔라스게임 사설게임 보솜이 상승추세 건전한소개팅 띠별운세 계수일간 무료캠채팅사이트 헌트 밍키넷야한만화 amouranth 롤러코스터수영장편 밤기닷컴 구자철한라봉합성사진 송중기노출 섹시섹스영화 후평동홀덤룰 현아화장실 로또복권당첨예상번호 음악중심애프터스쿨뱅 감전동룸싸롱 노포동립카페 신곡동홀덤카페 얼짱머리스타일 http://sarangvia.com 군자동유흥문화 천호동건마 행정동아로마마사지 zoosex 주가수익률 팔복동성인오락실 신길5동홀덤펍 페이스북아이콘 연천홀덤바 둔산동키스방 하계동출장마사지 태인면포커고수 교통방송라디오 평원동홀덤룰 오이넷 김시향친구들과번갈아노출 망포동가라오케 자양2동홀덤펍 hp프린트 엄궁동건마 하마사키마오 여드름에좋은천연팩 요정룸 이명박북한도발 야동카트 소리엘1집 유승호지연 배지현키 관고동퍼블릭룸 가즈아툰 코헤시브젤 마장동나이트 도봉동가라오케 당주동오마하홀덤 김영광외모비하 대방동인싸포커 개봉동홀덤바 효민연습실 야한장면 손나은엉덩이 금산면홀덤카페 해피아이돌친구 등촌3동홀덤바 에로영화다운 헨타이망가 2월코믹 화성홀덤펍 지변동인싸포커 구호동텍사스홀덤 한그루myboy가사 에스엠주식 연희동홀덤룰 운산동텍사스홀덤 아프리카4대여신수입 비키니할인 손나은허리돌림 생활낙원 명천동떡집 주원사진 야마토공략법 학하동성인게임장 근이완제 강산동풀싸롱 축구웃긴영상 장전동풀싸롱 눈물이주르륵뮤비 부송동홀덤바 안암동4가성인오락실 maiyamasaki 호성동홀덤카페 sexy가위바위보영상 지드래곤cafe 미산동유흥주점 x파일줄거리 신새롬 연천읍립카페 이기동홀덤족보 개운동홀덤펍 중국북한 오도동레깅스룸 역곡동홀덤카페 뇌졸중뇌졸증 북구립카페 반정동안마 섹스하는디지몬 영화누나 호리키타마키 소개팅미팅 조종면텍사스홀덤 http://xn--2i0bm4pftam9idvt.com 상암동홀덤룰 정우면인싸포커 퍼니툰 연예인비키니쇼핑몰 미원동홀덤룰 야한사람 등촌동모바일홀덤 구찌남자벨트 김민아 사우동텍사스홀덤 가수그룹 신석동오마하홀덤 무료채팅어플 아사다마오의상 오피러브 홍수아화보 정발산동오마하홀덤 정소민키스신 김태희합성사진 원천동북창pr 한국일본아이돌비교 에이핑크지나 엉덩이처진 애프터스쿨뱅뮤직뱅크 애니야한동영상사이트 신읍동가라오케 나눔콘서트아이유 세아라SC 동양ELW 코난TV 농소동인싸포커 롱삐삐 도계읍성인오락실 불가리가방토드백 지드래곤유두 움직이다 한선화움짤 개포동홀덤카페 생리대오버나이트가격 커플수영복추천 에스파일 CMC-A80 목상동대딸방 뮤직뱅크희철 Celine 690gbios 투자교육 힐링캠프한혜진노출 secret 포천유흥주점 예천동유흥주점 정동퍼블릭룸 은평구건마 코성형외과유명한곳 구찌가방223910 sexy게임 금상동홀덤바 구의1동홀덤바 연천읍나이트 http://m-powerball.com 가양동아로마마사지 상계동방석집 연정동홀덤카페 소시제시카노출 마산대딸방 내장동홀덤룰 행구동카지노펍 이민호 영웅문S수수료 에로틱장면 방배동유흥주점 78말띠클럽 코너스위트 김해대출 안전한사설놀이터추천 성복동성인게임장 성내동홀덤족보 성인용품가격 미니사전 양서면홀덤펍 싸이언카페폰 제시카동영상논란 상동성인오락실 지나첫눈에한눈에 파주모바일홀덤 예쁜아이돌 하안동홀덤룰 망포동키스방 강예빈떡 srace 양평동6가인싸포커 평릉동오마하홀덤 운양동텍사스홀덤 sexyshake라인댄스 삼영이엔씨주식 번3동성인오락실 핑클1집 진산동홀덤바 발목레깅스 선단동오마하홀덤 경암동홀덤펍 누드색스코리아 신공덕동나이트 신텍주식 아이스코어 읍내동안마 서서학동오마하홀덤 테리리처드슨 여자누드섹스 강남고급술집 원신흥동방석집 팔곡동아로마마사지 비래동퍼블릭룸 마두동홀덤룰 에르메스시계줄 석남동레깅스룸 암사동안마 뉴섹스코리아 친구현빈 마블툰 송정동오피 과해동모바일홀덤 인화동텍사스홀덤 이근호최희 동산면모바일홀덤 Theentertainer피아노연주 알몸카페 용동면텍사스홀덤 풍남동오마하홀덤 서완산동홀덤펍 용운동안마 전방주식 금천동성인오락실 수택동방석집 텐프로미 심곡본동키스방 신보라사랑합니다 화곡2동홀덤족보 화성인바이러스h컵녀 주미동유흥문화 자곡동성인오락실 퓨어제시카 장사동홀덤대회 사정동홀덤룰 쌍신동건마 고교서바이벌토론왕 공릉동아로마마사지 부곡동성인오락실 둔촌동방석집 일반인누드 보테가베네타남자지갑 물컹물컹 전곡읍방석집 우량종목 모의투자사이트 카지노 빙그레주식 명륜동홀덤바 호성동성인오락실 여의동오마하홀덤 별양동성인게임장 동광동오피 단대동모바일홀덤 장성동홀덤룰 뷰토렌트 임성민드레스 송월동홀덤바 이기광발기 STX주가전망 현아버블팝안무거울모드 색시만화책vip24변강쇠 산내동떡집 포항만남 미국중국 신방동유흥문화 고읍동북창pr 수유3동모바일홀덤 VfB뤼베크 기륭전자주식 아프리카티비 주교면떡집 가현동홀덤바 에스토릴프라이아 일직동퍼블릭룸 여자노출증 우명동풀싸롱 체코1LIGA 코어벳 아프리카티비19 성인애니메이션동영상 걸포동노래방 레이싱걸팬티스타킹 오룡동오마하홀덤 서초수련원 섹스파일 청담동홀덤룰 용운동유흥문화 비원에이포3월컴백 굴곡형임플란트 소격동홀덤바 인터넷주식방법 면팬티라이너 숭인동홀덤카페 교촌동아로마마사지 양평읍성인인형체험 손오공주식 생리하는동영상 translate 관문동유흥문화 http://powerballmania.com 신대방동,봉천동떡집 신탄진동출장마사지 회원정보수정 이승기김연아 취재기자연결합니다왜 송정동성인오락실 양전동홀덤대회 카지노위키 고천동가라오케 kofree코프리 장현동포커고수 미디어플렉스주식 망미동풀싸롱 쌍용동떡집 케이500 레드폭스 용인홀덤족보 파파로티 야동동나이트 남자스타킹 허벌라이프 마전동유흥문화 홍지동홀덤카페 유천동홀덤족보 성남호스트바 유노윤호키스신 화성인임재영싸이 학하동노래방 핑클노래 luckymizili 중앙동오마하홀덤 SWED2 세계에서가장작은 스타섹스 안암동홀덤바 현아징거 단발머리마쓰자키헤어 이화공영주식 다크브라운염색 국제결혼정보회사 방배동퍼블릭룸 창신2동홀덤족보 율정동홀덤카페 증권커뮤니티 http://musingame18.com 가희세바퀴 리지몸무게 배구 주니어속옷 트러블메이커안무거울모드 식사동리얼돌성인인형 차다혜성형 속옷모델 송선동가라오케 연애인비디오 요즘노래 지연또르르mr제거 장항동오피 KODEX에너지화학주식 먹튀검증업체순위 중요부위가려움 해리스타일스 라디오스타303회 구리떡집 나르샤비키니 아주야한것 키워드광고비용 십정동오피 강인정수정 녹산동가라오케 변동풀싸롱 여자야동 시계바늘듣기 증권토론 먹튀업체 뽀르노싸이트 김지원노출 양서면유흥거리 카트라이더유반장 세바퀴박은지 주례동나이트 동작구키스방 주식왕 먹튀폴리스믿을만 부산아트빈 강하면레깅스룸 모란출장마사지│태평출장마사지│경원대출장마사지 인천노래방 청학동키스방 토토핫 흥분시키는방법 티파니황미영 주당순이익 바다게임모음 옷벗고 고척동리얼돌성인인형 시로스카이 세계의아름다운해변 미산면건마 FXEURO 신부동출장마사지 산황동유흥거리 바다스톰릴깸 절대 먹튀업체 연지동룸싸롱 동암출장안마 성인뮤비 천안로또판매점 농협선물옵션 추천릴개임 rpg게임 천북면성인인형체험 예진움짤 한미글로벌주식 아파트분양 연예인소묘 BIG3 좋은번호 먹튀폴리스심바 하기동성인용품 미호동성인인형체험 akzkdh 정인영아나운서학력 asiasex 비에이피병맛만화 탄방동키스방 청소면아로마마사지 섹시화보귀여움 르노클리오 아이러브베이스볼 섹스장면 임부복레깅스 사정동대딸방 안전놀이터모음 이환경딸 증권가찌라시박시후 허가윤남지현 우장산출장마사지 노고산동가라오케 19금망가 먹튀폴리스검증업체 먹튀검증업체순위 단대동레깅스룸 남자건강보조제 스타킹꿀벅지 몰디브 단대동성인게임장 성남FC http://25-jungpoom.com 위야넷접속 영등포본동떡집 스테란 duwkwkawnl PORNHUB 코메도 마산립카페 먹튀검증커뮤니티 사설먹튀검증 교동가라오케 도봉동북창pr VAST 연예인속옷쇼핑몰 딸자닷컴서양야동 먹튀신고 청담동 둔곡동유흥거리 현금배당률 방화동건마 알소동 상승주가 주식사려면 궁정동건마 h컵화성인 게임메니아 양산풀싸롱 토토핫 남성수술 아이유딸용 토토핫 아비루유 샴푸나이트 일본중국축구 학하동대딸방 연예인허리돌림 주식무작정따라하기 빵빵넷 량현량하누나 대구유흥가 지포라이터 간호사색스 돈의화신황정음옷 한성주이휘재 떡카페 스포츠토토 오남동키스방 성인가수 남포동출장마사지 고기집떡춤녀 아이창고 바툰 금고동성인용품 영선동풀싸롱 여의동노래방 성인페티시 사진촬영알바 통합검색 베이글녀 마계촌온라인 http://sportstoto-v.com 슈퍼주니어중국 중앙경제연구원 득산동풀싸롱 후기가라오케 브랜뉴데이방송사고 연양동레깅스룸 씨스타노래모음 성인병치료방안 문산레깅스룸 용촌동안마 색스인터넷 스피드 무료주식 발기부전치료제 주식추천 연예인이름 애프터스쿨리지고등학교 v걸노출 지지미한국 유안초등학교 유가전망 주식신규 부비부비몽글몽글 배미동성인인형체험 모델노출 윤건 로또3등 김수정나이 각시탈 유탐 하소동토킹bar 홍순례 HIT보험주식 강랜e100x닷컴 도토리 soranet 원미동성인인형체험 오프스프링 북소녀시대 콘돈 김량장동떡집 오금동방석집 광저우아시안게임 소호동립카페 토렌트가가 럭셔리포르노 크리스탈유리 넷마블홀덤 쌍커풀수술 sbs아나운서 박효신별밤방송사고 펀드수수료 아이튠즈없이동영상넣기 지나산체스beautifulday반복... 500만원재테크 리서치결과 설운동유흥거리 네임드토토 국민주택채권할인 MS-ONLINE 도봉구키스방 레이젠주식 강상면퍼블릭룸 섹시한쇼핑몰 섹시여자 퓨처스리그분석 일본코스프레 주식시세 송파동오피 티스토리블로그 팬티스타킹가터벨트3화 빅사이즈브라탑 장안동대딸방 동영상프로그램 행운번호추출기 본동북창pr 큐렉소주식 문자천사 삼룡동성인게임장 뚜루왑뚜밥뚜밥 죽전동성인인형체험 청룡동대딸방 아미동유흥주점 토트넘경기 귀여운아이유 시흥리얼돌성인인형 꿀떡넷성인 한게임환전상naverad999.닷컴 안산토킹bar 목돈마련상품 판타지러너즈넥슨캐시 옥택연복근 섹시한섹시화보집속옷노출 문지동립카페 남자누드섹스 윙크티비지아 레드오션투자클럽 김연아레미제라블해외반응 동영상보기 소학동건마 티아라야캠 루이까또즈지갑 풍무동레깅스룸 희귀구멍 누드갤러리 실시간해외배당흐름사이트 일회용주사기 부부갈등 후지라텍스슬림2000 밤꽃야동 유세윤세바퀴 보아비스타FC 남지현포미닛 야플릭스 로또프로그램 애니팡도전장제한갯수 성인용품할인점 로또1등당첨자 일반인초미니스커트 야구리망가 섹시레슬링 남포면성인인형체험 중랑구립카페 티아라바탕화면 끌로에머니클립 HPV백신 봉천출장안마│신림출장안마│신대방출장안마 여자팝송추천 유리복근 신개념채팅 입장면북
전화번호 : 영업시간 :
홈페이지 : 위치정보 :

댓글목록

등록된 댓글이 없습니다.